Charles River Laboratories (NYSE:CRL) and MEDIPOST Co., Ltd. have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization.
This morning’s news release says the partnership will leverage Charles River’s expertise in biologics and cell therapy GMP testing to support MEDIPOST’s global cell therapy pipeline, starting in the Asia-Pacific (APAC) and North America (NA) regions, with possible expansion into Middle East and Europe.
“We are excited to deepen our partnership with MEDIPOST and collaborate with a top global cell therapy developer, assisting at both clinical and commercialization phases,” said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River. “By collaborating with industry leaders, we aim to expand GMP testing capabilities and help ensure that safe, compliant products reach patients more efficiently.”
Charles River will provide specialized expertise in biologics quality control, viral testing, release testing, and other GMP-compliant services, supporting MEDIPOST from development through commercialization.
“Through this non-exclusive MOU,” the release concludes, “Charles River continues to advance efficient, high-quality, and compliant development pathways for advanced biologics, particularly within the APAC region.”
CRL shares collapsed $6.12, or 3.6%, Wednesday to $162.57.
Related Stories
